Distinguished in Uveitis

Francesco M. Bandello

Department Of Otolaryngology Head And Neck Surgery, 
Milan, IT 
Distinguished in Uveitis
Department Of Otolaryngology Head And Neck Surgery, 
Milan, IT 
OverviewLocationsClinical Research

Overview

Francesco Bandello practices in Milan, Italy. Mr. Bandello is rated as a Distinguished expert by MediFind in the treatment of Uveitis. His top areas of expertise are Diabetic Macular Edema (DME), Late-Onset Retinal Degeneration, Age-Related Macular Degeneration (ARMD), Vitrectomy, and Cataract Removal.

His clinical research consists of co-authoring 1012 peer reviewed articles and participating in 7 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 40 articles in the study of Uveitis.

Gender
Male

Locations

Department Of Otolaryngology Head And Neck Surgery, Milan, Italy

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

7 Clinical Trials

Development of Novel Clinical Endpoints for Interventional Clinical Trials With a Regulatory and Patient Access Intention in Patients With Intermediate Age-related Macular Degeneration (AMD)
Development of Novel Clinical Endpoints for Interventional Clinical Trials With a Regulatory and Patient Access Intention in Patients With Intermediate Age-related Macular Degeneration (AMD)
Enrollment Status: Active_not_recruiting
Publish Date: January 16, 2025
Intervention Type: Other
Safety and Performance Evaluation of the NR600 System in Subjects With End-stage Inherited Outer Retinal Degenerative Diseases
Safety and Performance Evaluation of the NR600 System in Subjects With End-stage Inherited Outer Retinal Degenerative Diseases
Enrollment Status: Terminated
Publish Date: March 15, 2023
Intervention Type: Device
Study Phase: Not Applicable
A Prospective, Observer-masked, Randomized Clinical Trial to Investigate and Compare the Clinical Efficacy of Chloroprocaine 3% Gel and Tetracaine 0.5% Eye Drop as Topical Anestheticsin Phacoemulsification.
A Prospective, Observer-masked, Randomized Clinical Trial to Investigate and Compare the Clinical Efficacy of Chloroprocaine 3% Gel and Tetracaine 0.5% Eye Drop as Topical Anestheticsin Phacoemulsification.
Enrollment Status: Completed
Publish Date: January 18, 2023
Intervention Type: Drug
Study Phase: Phase 3
A Non-interventional Study of Clinical Experience in Patients Prescribed Raxone® for the Treatment of Leber's Hereditary Optic Neuropathy (LHON)
A Non-interventional Study of Clinical Experience in Patients Prescribed Raxone® for the Treatment of Leber's Hereditary Optic Neuropathy (LHON)
Enrollment Status: Completed
Publish Date: July 16, 2021
Intervention Type: Drug
Observational Registry Study of Leber Hereditary Optic Neuropathy (LHON) Affected Patients
Observational Registry Study of Leber Hereditary Optic Neuropathy (LHON) Affected Patients
Enrollment Status: Completed
Publish Date: February 08, 2021
Intervention Type: Other
An International, Multicenter, Randomized, Blinded-assessor, Parallel-group Clinical Study Comparing Eye Drops of Combined LEvofloxAcin + DExamethasone foR 7 Days Followed by Dexamethasone Alone for an Additional 7 Days vs. Tobramycin + Dexamethasone for 14 Days for the Prevention and Treatment of Inflammation and Prevention of Infection Associated With Cataract Surgery in Adults - LEADER 7
An International, Multicenter, Randomized, Blinded-assessor, Parallel-group Clinical Study Comparing Eye Drops of Combined LEvofloxAcin + DExamethasone foR 7 Days Followed by Dexamethasone Alone for an Additional 7 Days vs. Tobramycin + Dexamethasone for 14 Days for the Prevention and Treatment of Inflammation and Prevention of Infection Associated With Cataract Surgery in Adults - LEADER 7
Enrollment Status: Completed
Publish Date: August 18, 2020
Intervention Type: Drug
Study Phase: Phase 3
A Phase 2/3, Randomized, Double-Masked, Sham-Controlled Trial of QPI-1007 Delivered By Single or Multi-Dose Intravitreal Injection(s) to Subjects With Acute Nonarteritic Anterior Ischemic Optic Neuropathy (NAION)
A Phase 2/3, Randomized, Double-Masked, Sham-Controlled Trial of QPI-1007 Delivered By Single or Multi-Dose Intravitreal Injection(s) to Subjects With Acute Nonarteritic Anterior Ischemic Optic Neuropathy (NAION)
Enrollment Status: Terminated
Publish Date: July 20, 2020
Intervention Type: Other, Drug
Study Phase: Phase 2/Phase 3
View 6 Less Clinical Trials

1011 Total Publications

Self-inflicted Handheld Laser-induced Maculopathy.
Self-inflicted Handheld Laser-induced Maculopathy.
Journal: Ophthalmic surgery, lasers & imaging retina
Published: November 04, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Bandello's expertise for a condition
ConditionClose
View All 14 Elite Conditions
View All 11 Distinguished Conditions
View All 26 Advanced Conditions
View All 72 Experienced Conditions
Want to save this expert for later?
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile